Ensign Peak Advisors, Inc Ligand Pharmaceuticals Inc Transaction History

Ensign Peak Advisors, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$127.69 - $165.85 $1.14 Million - $1.47 Million	-8,890 Reduced 56.86%	6,744 $1.04 Million
Q4 2020 Feb 12, 2021	SELL	$80.55 - $106.05 $96,660 - $127,260	-1,200 Reduced 7.13%	15,634 $1.56 Million
Q3 2020 Nov 12, 2020	SELL	$89.56 - $126.72 $1.69 Million - $2.39 Million	-18,883 Reduced 52.87%	16,834 $1.61 Million
Q2 2020 Aug 12, 2020	BUY	$68.28 - $123.65 $1.29 Million - $2.33 Million	18,883 Added 112.17%	35,717 $4 Million
Q4 2019 Feb 14, 2020	BUY	$96.94 - $113.59 $1.63 Million - $1.91 Million	16,834 New	16,834 $1.76 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.01B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.